288.99 USD
-7.29
2.46%
At close Apr 21, 4:00 PM EDT
After hours
268.00
-20.99
7.26%
1 day
-2.46%
5 days
-3.16%
1 month
-10.87%
3 months
-16.84%
6 months
-18.11%
Year to date
-13.67%
1 year
-23.19%
5 years
266.69%
10 years
939.91%
 

About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Employees: 5,900

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

14% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 81

12% more call options, than puts

Call options by funds: $26.1M | Put options by funds: $23.4M

4% more repeat investments, than reductions

Existing positions increased: 214 | Existing positions reduced: 206

0% more capital invested

Capital invested by funds: $8.38B [Q3] → $8.4B (+$26.7M) [Q4]

0.31% more ownership

Funds ownership: 81.06% [Q3] → 81.38% (+0.31%) [Q4]

0% more funds holding

Funds holding: 577 [Q3] → 578 (+1) [Q4]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 6 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$328
13%
upside
Avg. target
$342
18%
upside
High target
$362
25%
upside

5 analyst ratings

positive
20%
neutral
80%
negative
0%
TD Cowen
Charles Rhyee
11% 1-year accuracy
1 / 9 met price target
14%upside
$328
Hold
Downgraded
14 Apr 2025
Truist Securities
Jailendra Singh
34% 1-year accuracy
12 / 35 met price target
15%upside
$333
Hold
Maintained
10 Apr 2025
Mizuho
Ann Hynes
67% 1-year accuracy
16 / 24 met price target
23%upside
$355
Outperform
Maintained
9 Apr 2025
Leerink Partners
Michael Cherny
67% 1-year accuracy
20 / 30 met price target
14%upside
$330
Market Perform
Initiated
24 Mar 2025
Baird
Eric Coldwell
38% 1-year accuracy
12 / 32 met price target
25%upside
$362
Neutral
Maintained
27 Jan 2025

Financial journalist opinion

Based on 9 articles about MEDP published over the past 30 days

Neutral
Business Wire
4 hours ago
Medpace Holdings, Inc. Reports First Quarter 2025 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue for the three months ended March 31, 2025 increased 9.3% to $558.6 million, compared to $511.0 million for the comparable prior-year period. On a constant currency basis, revenue for the first quarter of 2025 increased 9.5% compared to the first quarter of 2024. Backlog as of March 31, 2025 decre.
Medpace Holdings, Inc. Reports First Quarter 2025 Results
Negative
Zacks Investment Research
1 week ago
Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for
Positive
Zacks Investment Research
1 week ago
CON vs. MEDP: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
CON vs. MEDP: Which Stock Is the Better Value Option?
Positive
Zacks Investment Research
1 week ago
Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains?
Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains?
Neutral
Zacks Investment Research
2 weeks ago
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Medpace (MEDP) closed at $290.10, marking a +1.04% move from the previous day.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
Positive
The Motley Fool
2 weeks ago
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit.
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Neutral
Seeking Alpha
2 weeks ago
Medpace Holdings: It Might Be Time To Buy In
Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties around pharmaceutical spending and backlogs, which could make the current valuation appear too high.
Medpace Holdings: It Might Be Time To Buy In
Positive
Zacks Investment Research
4 weeks ago
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Medpace (MEDP) closed at $330.59 in the latest trading session, marking a +1.96% move from the prior day.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Positive
Zacks Investment Research
4 weeks ago
CON or MEDP: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
CON or MEDP: Which Is the Better Value Stock Right Now?
Neutral
Business Wire
1 month ago
Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 1.
Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025
Charts implemented using Lightweight Charts™